Investing.com -- Morgan Stanley upgraded its rating on Zealand Pharma (NASDAQ: ZEAL) shares to Overweight from Equal Weight, ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Investing.com -- Morgan Stanley (NYSE:MS) upgraded its rating on Zealand Pharma (NASDAQ:ZEAL) shares to Overweight from Equal Weight, highlighting a “long-term obesity potential” unlocked by the ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema ... for such products to launch, however, with Zealand Pharma's CEO and President Adam Steensberg telling ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing ...

Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Comcast Corp.

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

The glucagon/GLP-1 receptor dual agonist – partnered with Zealand Pharma and also known as BI 456906 – achieved up to 19% weight loss in people living with overweight or obesity in a study ...

The Artisan International Small-Mid Fund portfolio outperformed the MSCI ACWI ex USA SMID Index in Q4 of 2024. Click here to ...